A detailed history of Fieldpoint Private Securities, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Fieldpoint Private Securities, LLC holds 2,804 shares of ARWR stock, worth $55,379. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,804
Previous 2,983 6.0%
Holding current value
$55,379
Previous $137,000 27.74%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$27.79 - $50.61 $4,974 - $9,059
-179 Reduced 6.0%
2,804 $99,000
Q1 2022

Apr 07, 2022

SELL
$39.62 - $69.97 $792 - $1,399
-20 Reduced 0.67%
2,983 $137,000
Q4 2021

Jan 24, 2022

SELL
$58.09 - $82.51 $1,161 - $1,650
-20 Reduced 0.66%
3,003 $199,000
Q3 2021

Nov 12, 2021

BUY
$58.38 - $84.96 $1,050 - $1,529
18 Added 0.6%
3,023 $189,000
Q2 2021

Aug 12, 2021

SELL
$62.15 - $90.32 $2,050 - $2,980
-33 Reduced 1.09%
3,005 $184,000
Q1 2021

Apr 23, 2021

SELL
$61.35 - $90.47 $48,527 - $71,561
-791 Reduced 20.66%
3,038 $201,000
Q4 2020

Jan 28, 2021

BUY
$43.82 - $85.37 $167,786 - $326,881
3,829 New
3,829 $294,000
Q2 2020

Aug 14, 2020

SELL
$26.12 - $43.27 $283,872 - $470,258
-10,868 Closed
0 $0
Q1 2020

May 11, 2020

SELL
$20.56 - $63.12 $1,788 - $5,491
-87 Reduced 0.79%
10,868 $312,000
Q4 2019

Feb 10, 2020

BUY
$28.14 - $73.01 $192,815 - $500,264
6,852 Added 167.0%
10,955 $695,000
Q3 2019

Nov 07, 2019

SELL
$26.26 - $34.86 $9,269 - $12,305
-353 Reduced 7.92%
4,103 $116,000
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $77,668 - $128,421
4,456 New
4,456 $118,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.09B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Fieldpoint Private Securities, LLC Portfolio

Follow Fieldpoint Private Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fieldpoint Private Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fieldpoint Private Securities, LLC with notifications on news.